Showing 4821-4830 of 5964 results for "".
- Online Care May Be As Effective as In-Person Care for Psoriasishttps://practicaldermatology.com/news/online-care-may-be-as-effective-as-in-person-care-for-psoriasis/2457574/Teledermatology may be as effective as seeing a doctor in person when it comes to improving the symptoms of psoriasis, according to a new study in JAMA Network Open. “Patients with chronic skin diseases need ongoing care, and depending on where they live, their access to de
- Veloce BioPharma Announces Positive Phase 2b Study Results for VBP-926 for Chemotherapy-Associated Paronychiahttps://practicaldermatology.com/news/veloce-biopharma-announces-positive-phase-2b-study-results-for-vbp-926-for-chemotherapy-associated-paronychia/2457580/Veloce BioPharma, LLC, a clinical-stage biopharmaceutical company dedicated to developing topical therapeutics for unmet needs in dermatologic and ophthalmic diseases, shared positive results of its Phase 2b study of dilute povidone-iodine in a novel DMSO solvent system for the topical treatment
- FDA Approves Paratek's Nuzyrahttps://practicaldermatology.com/news/fda-approves-parateks-nuzyra/2457579/The FDA has approved Paratek Pharmaceuticals, Inc's Nuzyra (omadacycline) for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI). Nuzyra, a modernized tetracycline, is a once-daily IV and or
- Dermira's Qbrexa Cloth Now Available for Primary Axillary Hyperhidrosishttps://practicaldermatology.com/news/dermiras-qbrexa-cloth-now-available-for-primary-axillary-hyperhidrosis/2457582/Dermira, Inc.'s Qbrexa (glycopyrronium) cloth is now available for prescribing to treat primary axillary hyperhidrosis. The new therapy is available in retail and community pharmacies nationwide. In June 2018, QBREXZA, a once-daily, prescription anticholinergic, was FDA approved to treat adul
- Is Teen Acne a Sign of Future Financial Success?https://practicaldermatology.com/news/is-teen-acne-a-sign-of-future-financial-success/2457586/The love of books, the need for glasses and high intelligence are traits found among the top earners in many fields across the country, and now, a Ball State University researcher suggests that teen acne may also be on this list. In his study, “
- Seysara: Oral Antibiotic is First Approved for Dermatology in 40 Yearshttps://practicaldermatology.com/news/seysara-oral-antibiotic-is-first-approved-for-dermatology-in-40-years/2457584/Seysara (sarecycline), a new, first in class tetracycline-derived oral antibiotic, is now approved for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. Almirall, which recently acquired Seysara from Allergan, plans to laun
- Ortho Dermatologics' Bryhali Lotions Performs Well in Two Phase 3 Psoriasis Trialshttps://practicaldermatology.com/news/ortho-dermatologics-psoriasis-drug-bryhali-performs-well-in-two-phase-3-trials/2457585/Two Phase 3 randomized controlled trials show that Bryhali (halobetasol propionate) Lotion, 0.01%, an investigational potent to superpotent corticosteroid in the treatment of moderate-to-severe plaque psoriasis, is effective and well-tolerated. Bryhali Lotion has a Prescription Drug
- What Happens When "Award Winning Hair Transplant Surgeons Meet"?https://practicaldermatology.com/news/what-happens-when-award-winning-hair-transplant-surgeons-meet/2457587/Boasting "true star power" with a lineup of international speakers and educational offerings in the ever-expanding field of hair transplant surgery, the 26th World Congress of the International Society of Hair Restoration Surgery (ISHRS) heads to Hollywood October 10-14.&
- FDA Approves Regeneron's Libtayo, First Treatment for Metastatic or Locally Advanced SCChttps://practicaldermatology.com/news/fda-approves-regenerons-libtayo-first-treatment-for-metastatic-or-locally-advanced-scc/2457589/Libtayo (cemiplimab-rwlc) injection (Regeneron Pharmaceuticals, Inc.) is now FDA-approved for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiatio
- Bellus Medical Now Part of Crown Laboratorieshttps://practicaldermatology.com/news/bellus-medical-now-part-of-crown-laboratories/2457590/Crown Laboratories, Inc. and Hildred Capital Partners, LLC have acquired Bellus Medical. Bellus’s non-invasive offerings include the SkinPen, a medical grade microneedling device used exclusively by healthcare professionals to improve the appearance of facial acne scars. It is the f